Related Experiment Video
Updated: Jul 3, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
[Hormone replacement therapy in peri- and postmenopausal women and breast cancer risk]
Stefan Buchholz1, Felicitas Horn, Olaf Ortmann
1Klinik für Frauenheilkunde und Geburtshilfe der Universität Regensburg, Caritaskrankenhaus St. Josef, Regensburg.
Abstract:
Hormone therapy (HT), in peri- and postmenopause has been associated with a modest increase in the risk of breast cancer. Hormones play a major role in tumorigenesis of breast cancer, and reproductive factors are known to influence breast cancer risk. Female sex steroids are used for contraception or menopause treatment by women of reproductive age and postmenopausal women respectively. This review reports recent published epidemiological evidence and randomised trials which examined the effect of HT on the risk of breast cancer.
Related Concept Videos
Menopause
Disorders of the Female Reproductive System
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Bone Remodeling
